Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: Trial design and methodology |
| |
Institution: | 1. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada;2. Department of Laboratory Medicine and Keenan Research Centre for Biomedical Science, St. Michael''s Hospital, 30 Bond Street, Toronto M5B1W8, Canada;3. Keenan Research Centre for Biomedical Science, St. Michael''s Hospital, 30 Bond Street, Toronto M5B1W8, Canada;4. Department of Endocrinology and Metabolism, Huashan Hospital, Medical College, Fudan University, Shanghai 200040, China;5. Department of Physiology, Faculty of Medicine, University of Toronto, Canada;6. Department of Medicine, Faculty of Medicine, University of Toronto, Canada;7. Division of Endocrinology and Metabolism, Keenan Research Centre for Biomedical Science of St. Michael''s Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada |
| |
Abstract: | BackgroundEvidence suggests that GABA may reduce pancreatic inflammation, protect β-cells from autoimmune destruction, and potentiate the regeneration of new β-cells in the setting of type 1 diabetes mellitus (T1DM). The enzyme GAD, also expressed in human pancreatic β-cells, is an antigenic target of reactive T cells. We hypothesized that treatment of children with recent onset T1DM with GABA or combination GABA with GAD will preserve β-cell function and ameliorate autoimmune dysregulation.MethodsThis is a one-year, prospective, randomized, double-blind, placebo-controlled trial. Ninety-nine patients aged 4–18 years with newly diagnosed T1DM are randomized into three treatment groups: 1) oral GABA twice daily in addition to two injections of recombinant GAD enzyme, 2) oral GABA plus placebo GAD injections, or 3) placebo GABA and placebo GAD. Patients are evaluated at baseline and months 1, 5, 8 and 12. Mixed meal tolerance testing is performed at all but the 8-month visit. Laboratory studies will assess indices of beta and alpha cell function, glycemic control, immunophenotyping, and diabetes-related autoantibodies.ResultsThe primary outcome is the effect on pancreatic β-cell function as measured by meal-stimulated c-peptide secretion compared between the treatment groups before and after one year of treatment. Secondary outcomes include: 1) fasting and meal stimulated glucagon and proinsulin levels, 2) response in insulin usage by participants, 3) indices of immune cell function, and 4) effect on autoantibodies GAD65, ICA512, and ZnT8.Conclusions: This trial will determine the safety and efficacy of GABA and combination GABA/GAD therapy to delay T1DM progression in children. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|